Doxycycline for Hereditary Hemorrhagic Telangiectasia

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 12, 2018

Primary Completion Date

February 18, 2021

Study Completion Date

March 1, 2021

Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
DRUG

Doxycycline Hyclate

Doxycycline will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)

DRUG

Placebo

Placebo will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)

Trial Locations (1)

M5B 1W8

St. Michael's Hospital, Toronto

All Listed Sponsors
collaborator

Barrow Neurological Institute

OTHER

collaborator

Duke University

OTHER

collaborator

Feinstein Institute for Medical Research

OTHER

collaborator

University of Pittsburgh

OTHER

collaborator

Sunnybrook Health Sciences Centre

OTHER

lead

Unity Health Toronto

OTHER